"4C-amodiaquin and "4C-chloroquine were used to study drug binding by preparations of owl monkey erythrocytes infected either with a chloroquine-susceptible (CS) or with a chloroquine-resistant (CR) strain of P. falciparum. Both of these drugs are derivatives of 4-aminoquinoline, but they differ in their side chains, and there are differences in the way they are handled by preparations of erythrocytes infected with malaria parasites. Although the apparent association constant for the binding of either drug is approximately 107 mol-1, two to three times more radioactivity was bound from "4C-amodiaquin than from "C-chloroquine. Furthermore, there was no apparent difference between CS and CR parasites with respect to "4C-amodiaquin binding, whereas erythrocytes infected with CR parasites have a deficiency of "4C-chloroquine binding. This difference in the handling of amodiaquin probably accounts for its superiority in the treatment of the owl monkey and of humans infected with CR P. falciparum.
More than 2 The superiority of amodiaquin in treating chloroquine-resistant malaria is of interest because amodiaquin and chloroquine differ structurally only in their side chains. Both drugs are derivatives of 7-chloro-4-aminoquinoline and both have side chains terminating in a diethylamino group (Fig. 1) . In amodiaquin, the diethylamino group is attached to 4-aminoquinoline through o-cresol, as illustrated in Fig. 1 ; in chloroquine, the attachment is through an isopentyl group. This structural difference evidently affects the interactions of these drugs with malaria parasites.
An important interaction of chloroquine with CS malaria parasites is its binding to a drug receptor (2, 3) , which probably is located on or near food vacuoles (1) bind only 1.1 ,umol of chloroquine with similar affinity. These and other observations (Fitch, Proc. Helminthol. Soc. Wash., Suppl., in press) provide support for the hypothesis that binding of chloroquine and related drugs to a highaffinity drug receptor is essential for their chemotherapeutic action. To investigate the relationship between drug binding and therapeutic effectiveness, the following studies of 4C-amodiaquin binding were undertaken.
MATERIALS AND METHODS
Owl monkeys in routine passage lines either for the CS Malayan Camp-CH/Q strain or for the CR Vietnam Oak Knoll strain of P. falciparum were provided by L. H. Schmidt; uninfected monkeys served as an additional control. The monkeys were infected by intravenous administration of blood containing approximately 104 parasites, and blood was obtained for study 9 to 12 days later when the parasitemias ranged from 1,320 to 2,880 parasites per 10,000 erythrocytes.
Radiochemically pure "4C-amodiaquin [4- 
] with a specific activity of 1.21 mCi/rnmol was provided by A. J. Glazko. The molecule was labeled in the methylene bridge as is shown in Fig. 1 .
The methods used to measure amodiaquin binding by preparations of washed erythrocytes in vitro were similar to those already described for studies of chloroquine binding (2, 3) . Thus, washed erythrocytes were incubated for 30 to 60 min in media containing graded amounts of '4C-amodiaquin. At the end of incubation, the cells were separated from medium by centrifugation, and a sample of the medium was transferred to a counting vial for measurement of radioactivity with a liquid scintillation spectrometer and a xylene-dioxane-2-ethoxyethanol (1: 3: 3) counting solution. The channels ratio method was used to correct for quenching by these aqueous solutions. All samples were counted for a sufficient length of time to achieve a probable error of counting of 2% or less.
The amounts of radioactivity in erythrocyte pellets were calculated by subtracting the amount of radioactivity in the medium at the end of incubation from the amount added at the beginning of incubation. In latex experiments in which mouse erythrocytes infected with P. berghei were used, 95% or more of the radioactivity calculated in this way to be present in erythrocyte pellets was recovered when nonradioactive chloroquine was added to the pellet at the end of incubation to displace the radioactive amodiaquin or its metabolites.
In the present studies, some of the preparations of erythrocytes were divided into a sufficient number of parts to allow chloroquine and amodiaquin binding to be measured concurrently. The methods used to measure chloroquine binding have been described in detail previously (2) . The chloroquine-3-"4C used in these studies had a specific activity of 1.71 mCi/mmol and was obtained from New England Nuclear Corp. The position of the label in the chloroquine molecule is shown in Fig. 1 .
RESULTS
The accumulation of radioactivity in erythrocytes incubated with "C-amodiaquin is shown in Fig. 2 . Only values from 60-min periods of incubation are shown, as there was no difference between 30-and 60-min values, i.e., steady-state conditions prevailed. Since metabolism of amodiaquin may have occurred during incubation, it is possible that the radioactivity in pellets and medium does not represent amodiaquin alone. For this reason, in Fig. 2 (3) .
From the data shown in Fig. 2 , the maximal capacity of preparations of erythrocytes infected with P. falciparum to bind amodiaquin or its metabolites with an apparent association constant of approximately 107 is estimated to be 10 umol per kg (wet weight). This value is two to three times greater than the maximal capacity of comparable preparations of erythrocytes infected with CS P. falciparum to bind chloroquine with similar affinity (cf. Fig. 2 and 3) .
The results of studies of chloroquine binding are shown in Fig. 3 . These additional studies were needed because the CR strain of P. fal- ciparum used in the present work was different from the Vietnam Monterey strain used in the earlier study (3) . To facilitate comparison, the new data for chloroquine binding are superimposed on a previously published figure that summarizes the older data. This comparison demonstrates that the Oak Knoll strain of P. falciparum has a deficiency of chloroquine binding similar to that of the Monterey strain. It is noteworthy that erythrocyte preparations which bound the least radioactivity from 14C-amodiaquin also bound the least 14C-chloroquine. Whether or not the 14C-chloroquine was metabolized was not determined in these studies.
DISCUSSION
As would be predicted from structural similarities (Fig. 1 ), amodiaquin competes with chloroquine for the high-affinity drug receptor of P. berghei (Fitch, Proc. Helminthol. Soc. Wash., Suppl., in press), and, as would be predicted for two drugs acting through the same receptor, CR P. berghei exhibits cross-resistance to amodiaquin (5). Because CR P. falciparum also exhibits a degree of cross-resistance to amodiaquin, it is tempting to conclude by analogy that amodiaquin and chloroquine are served by the same drug receptor in P. falciparum. This conclusion is not justified, however, until the differences in handling of "4C-amodiaquin and "4C-chloroquine ( Fig. 2  and 3 ) are adequately explained. These differences could be explained either by greater access of amodiaquin to a single type of receptor serving both drugs or by the existence of two types of receptors, one for each drug. In the former case, intact ability to accumulate radioactivity from "C-amodiaquin (Fig. 2 ) despite a deficiency of chloroquine binding (Fig. 3) 
